OTX-2002 is our lead Omega Epigenomic Controller™ (OEC) candidate designed to downregulate the expression of c-Myc (MYC), a key gene involved in cellular growth commonly overexpressed in cancer cells. OECs are programmable mRNA medicines that encode a two-part protein: a DNA binding domain that specifies the target location on the DNA, which we call EpiZips™, and an effector domain that makes precise and durable epigenetic marks to alter gene expression. OECs are translated into proteins by the cell’s ribosomal machinery, then travel to the nucleus to lay epigenetic marks at the programmed specific genomic address.